Health and Healthcare
Mixed Short Interest in Drug & Medical Stocks (June 2007)
Published:
As you will see, the short interest changes in medical and drug stocks of the active NYSE-listed names was a bit of a mixed bag. GlaxoSmithkline (GSK) saw the lagest increase, but its short interest is not representative of its real size or activity because it is an ADR and less active here compared to U.K. trade volume. We ranked hese in terms of percentages with the largest increase in short interest first.
STOCK (Ticker) JUNE07 MAY07 Change
GlaxoSmithkline (GSK) 7.74M 4.15M +86%
Boston Scientific (BSX) 32.07M 24.06M +33.3%
Wyeth (WYE) 3.3M 10.37M +28.3%
Labcorp (LH) 4.11M 3.21M +28%
Bristol-Myers (BMY) 26.95M 23.85M +13%
Schering-Plough (SGP) 16.79M 15.27M +9.9%
Medtronic (MDT) 16.11M 15.19M +6%
Pfizer (PFE) 54.48M 52.12M +4.5%
Quest Diagnost. (DGX) 18.00M 17.54M +2.6%
Merck (MRK) 22.82M 22.55M +1.2%
Eli Lilly (LLY) 13.77M 14.07M -2.1%
J&J (JNJ) 15.37M 16.16M -4.9%
Zimmer Holdings (ZMH) 3.89M 4.13M -5.8%
St. Jude MEdical (STJ) 6.53M 7.13M -8.4%
Genentech (DNA) 6.87M 8.16M -15.9%
Abbott Labs (ABT) 11.74M 16.39M -28.3%
Jon C. Ogg
June 24, 2007
Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.